In a recent transaction, Haemonetics Corp 's (NYSE:HAE) Executive Vice President and Chief Technology Officer, Anila Lingamneni, sold 2,305 shares of the company's common stock. The sale, which took place on May 6, 2024, was executed at a price of $95.00 per share, amounting to a total value of $218,975.
This transaction was carried out under an existing 10b5-1 trading plan, which had been fully executed as of June 5, 2023. A 10b5-1 trading plan allows company insiders to sell shares at predetermined times to avoid accusations of insider trading.
Following this sale, Lingamneni's remaining stake in Haemonetics includes 12,295 shares. It is important to note that this figure also comprises unvested restricted stock units that were previously reported, as well as 289 shares that were acquired under the company's 2007 Employee Stock Purchase Plan on April 30, 2024.
Haemonetics Corp, based in Boston, Massachusetts, specializes in surgical and medical instruments and apparatus. The company's stock is publicly traded on the New York Stock Exchange under the ticker symbol HAE.
Investors often monitor the buying and selling activities of company executives as it can provide insights into their perspective on the company's future performance. However, it's also common for executives to sell shares for personal financial planning, diversification, or liquidity reasons, which are not necessarily indicative of their outlook on the company's future.
The sale was officially filed with the Securities and Exchange Commission on May 8, 2024, and the details of the transaction are publicly accessible for investors' review.
InvestingPro Insights
As Haemonetics Corp (NYSE:HAE) sees its executives navigate their stock holdings, investors are keen to understand the underlying value and growth prospects of the company. With a market capitalization of $4.74 billion and a P/E ratio standing at 37.31, Haemonetics appears to be trading at a high earnings multiple. This is further reflected in the adjusted P/E ratio for the last twelve months as of Q3 2024, which sits at 31.67.
Revenue growth remains a bright spot, with a 12.48% increase reported over the last twelve months as of Q3 2024. This financial health is supported by a strong gross profit margin of 54.1%, indicating the company's ability to maintain profitability through its operations. Notably, Haemonetics has demonstrated a robust return over the last three months, with a 21.88% price total return, signaling investor confidence and a potentially bullish outlook for the stock.
From an investment strategy standpoint, an InvestingPro Tip suggests caution as the stock's Relative Strength Index (RSI) indicates it is currently in overbought territory. Additionally, the company is trading near its 52-week high, with the price at 96.18% of this peak. This could imply that the stock's current momentum has been recognized by the market, and investors may want to watch for signs of consolidation or pullback.
For those looking to delve deeper into Haemonetics' potential and gather more strategic insights, there are additional InvestingPro Tips available. In fact, there are 11 more tips listed on InvestingPro that could guide investors in making more informed decisions. To access these valuable insights, consider using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/HAE.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.